Firefly Neuroscience, Inc. (AIFF) stock analysis

Technology · Software - Application

From the 10-K filed 2026-03-31

How it makes money

It generates recurring revenue through subscriptions from clinics that use its hardware and software to perform brain function assessments.

Clinics pay for access to the platform, which provides structured reports from EEG and ERP brain activity data. Revenue scales directly with clinical utilization, as higher usage increases both the recurring fees earned and the proprietary data collected, which the company claims improves its reports.

The business relies on the persistent integration of these assessments into standard clinical workflows, meaning success depends on providers choosing to use the technology as part of their routine care for neurological or psychiatric patients.

What protects it: the moat

It asserts that its competitive advantage is a proprietary database and an integrated diagnostic platform that compounds in value over time.

Management describes this as a 'Flywheel' effect where every scan performed by a clinic increases the depth of its data, supposedly creating a more intelligent report for future users. The company claims this integrated system differentiates its offering from standard behavioral tools, though it relies on its ability to maintain and scale this network across clinical sites.

What growth costs

It must fund ongoing commercial deployment, product development, and operational expenses, which currently exceed its incoming cash.

The company incurs significant operating costs to support its network of clinical sites and develop its platform. It does not provide specific breakdowns for R&D or maintenance versus growth, but indicates that its ability to scale depends on securing additional financing due to recurring losses and negative cash flows.

What could damage it

Its inability to secure continuous external funding could lead to an immediate cessation of all commercial and developmental operations.

Because the company is currently unprofitable and reliant on external capital to bridge its cash shortfall, a failure to raise funds would force it to halt its expansion and product support. This would cause clinics to abandon the platform, breaking the 'Flywheel' cycle of data acquisition that underpins its business model.

About Firefly Neuroscience, Inc.

Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.

Other companies in Software - Application